Increased Fatigue May Predict CLL Disease Progression
October 11, 2024
Based on outcomes reported by patients, increased fatigue may predict disease progression in relapsed CLL / SLL patients on ibrutinib or zanubrutinib.
Based on outcomes reported by patients, increased fatigue may predict disease progression in relapsed CLL / SLL patients on ibrutinib or zanubrutinib.
Fatigue is one of the most common symptoms experienced by those living with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), and it is also commonly overlooked, underreported, and undertreated.
Fatigue is one of the most common symptoms experienced by those living with CLL and SLL, and it is also commonly overlooked,underreported, and undertreated.
Ask the Doctor Question: I was diagnosed with CLL in 2015 and on watch and wait, with good bloods. I am Stage A/0. I was a Specialist Biomedical Scientist in the
CLL patients often have suboptimal COVID-19 vaccine responses and worse outcomes. GEO-CM04S1, a new type of vaccine, results in stronger T cell immunity.
People with CLL deserve accurate diagnosis, holistic care, and a voice in decision-making. This charter reflects input from patients, advocates, and experts.
People with CLL benefit from exercise, likely improving quality of life, yet they are rarely “prescribed” it and are less active than their peers.
Access important medications in the CLL Society Clinician Medicine Cabinet. Download key resources and order a Welcome Kit.
Discover CLL Society Clinician Resource Library CME offerings to improve care approaches for CLL and SLL patients.